Literature DB >> 18925509

Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin.

A L Khandoga1, Y Fujiwara, P Goyal, D Pandey, R Tsukahara, A Bolen, H Guo, N Wilke, J Liu, W J Valentine, G G Durgam, D D Miller, G Jiang, G D Prestwich, G Tigyi, W Siess.   

Abstract

Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA(1-3)) and the newly identified LPA(4-7) subcluster. LPA(4), LPA(5) and LPA(7) increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA(1-7) GPCR in human platelets and found a rank order LPA(4) = LPA(5) > LPA(7) > LPA(6) = LPA(2) >> LPA(1) > LPA(3). We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA(1-5) receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 microM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC(50) of 1.1 microM but had no effect on the activation of LPA(1,2,3,&5) expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA(4) activation and shifted the dose-response curve to the right. LPA(5) transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA(1-5), and the receptor(s) mediating LPA-induced platelet activation remains elusive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925509      PMCID: PMC2757127          DOI: 10.1080/09537100802220468

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  35 in total

Review 1.  International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Edward J Goetzl; Timothy Hla; Yasuyuki Igarashi; Kevin R Lynch; Wouter Moolenaar; Susan Pyne; Gabor Tigyi
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

2.  Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.

Authors:  Akira Tokumura; Junya Sinomiya; Seishi Kishimoto; Tamotsu Tanaka; Kentaro Kogure; Takayuki Sugiura; Kiyoshi Satouchi; Keizo Waku; Kenji Fukuzawa
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

3.  Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.

Authors:  K Bandoh; J Aoki; A Taira; M Tsujimoto; H Arai; K Inoue
Journal:  FEBS Lett       Date:  2000-07-28       Impact factor: 4.124

4.  Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood.

Authors:  Takamitsu Sano; Daniel Baker; Tamas Virag; Atsushi Wada; Yutaka Yatomi; Tetsuyuki Kobayashi; Yasuyuki Igarashi; Gabor Tigyi
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

5.  Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  K Motohashi; S Shibata; Y Ozaki; Y Yatomi; Y Igarashi
Journal:  FEBS Lett       Date:  2000-02-25       Impact factor: 4.124

6.  Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.

Authors:  Kotaro Hama; Koji Bandoh; Yoshiyuki Kakehi; Junken Aoki; Hiroyuki Arai
Journal:  FEBS Lett       Date:  2002-07-17       Impact factor: 4.124

7.  Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family.

Authors:  Kyoko Noguchi; Satoshi Ishii; Takao Shimizu
Journal:  J Biol Chem       Date:  2003-04-30       Impact factor: 5.157

8.  Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.

Authors:  Enno Rother; Richard Brandl; Daniel L Baker; Pankaj Goyal; Harry Gebhard; Gabor Tigyi; Wolfgang Siess
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

Review 9.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 10.  Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate.

Authors:  Wolfgang Siess
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  17 in total

1.  Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Authors:  Carl Högberg; Olof Gidlöf; Francesca Deflorian; Kenneth A Jacobson; Aliaa Abdelrahman; Christa E Müller; Björn Olde; David Erlinge
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

Review 2.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

3.  Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children.

Authors:  José A Guerrero; José Rivera; Teresa Quiroga; Angel Martinez-Perez; Ana Isabel Antón; Constantino Martínez; Olga Panes; Vicente Vicente; Diego Mezzano; José-Manuel Soria; Javier Corral
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

4.  Lysophosphatidic acid produced by hen egg white lysophospholipase D induces vascular development on extraembryonic membranes.

Authors:  Junichi Morishige; Yoshihiro Uto; Hitoshi Hori; Kiyoshi Satouchi; Tanihiro Yoshiomoto; Akira Tokumura
Journal:  Lipids       Date:  2013-02-06       Impact factor: 1.880

Review 5.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

Review 6.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

7.  A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay.

Authors:  Jonathan K Fleming; Thomas R Glass; Steve J Lackie; Jonathan M Wojciak
Journal:  J Lipid Res       Date:  2016-07-21       Impact factor: 5.922

Review 8.  Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.

Authors:  Abby L Parrill; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2012-09-12

9.  Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.

Authors:  Jesica R Williams; Anna L Khandoga; Pankaj Goyal; James I Fells; Donna H Perygin; Wolfgang Siess; Abby L Parrill; Gabor Tigyi; Yuko Fujiwara
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

Review 10.  Lysophosphatidic acid in atherosclerotic diseases.

Authors:  Andreas Schober; Wolfgang Siess
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.